Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is suspected to be a scam, with users doubting its legitimacy and effectiveness. Many recommend using proven treatments like finasteride and minoxidil.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

The conversation discusses why CB-03-01, a potential hair loss treatment, isn't widely discussed despite evidence of its effectiveness and safety. Some users mention other treatments like melatonin, procianidin b2, and RU58841, debating their effectiveness and safety.

RU58841 has significantly improved the user's hair loss experience, alongside oral finasteride, dutasteride, 5 mg minoxidil, topical finasteride, dermastamping, and low-level laser therapy. The user is considering increasing their RU58841 dose from 75 mg to 100-150 mg daily.

User reports 3-month progress using daily 1mg finasteride, 0.5ml minoxidil (2x daily), 0.5ml dutasteride, and derma rolling 0.5mm 1-2 times per week. They see increased density on crown and top of head, slight progress in corners and temples, and recently added cosmerna.

Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.

PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.

A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.

The conversation is about making a topical solution from clascoterone powder, with references to using a RU58841 mixing guide for guidance. Concerns about product authenticity and bulk purchase requirements are also discussed.

The user has been using Minoxidil and finasteride with success and is now trying Dualgen-5R with retinoic acid but without finasteride, along with microneedling. They plan to share results in 5-6 months.

A user shared impressive hair regrowth results after 4 months using topical minoxidil, oral finasteride, and 3 PRP sessions. They plan to continue with these treatments and add dermastamping.

Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.

Hair loss progress update: finasteride, minoxidil, dermaroll, nizoral. Dermaroll depth 1.5mm, 3 times a week.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

PP405 is discussed as a potential alternative to finasteride, but its effectiveness and market availability are uncertain. Users share experiences with finasteride, minoxidil, and topical treatments, noting side effects and application techniques.

Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.

PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

The conversation is about starting a Discord group for people using KX-826 as their only treatment for hair loss, excluding those who are not serious or use multiple treatments. Someone agrees with the idea but mentions "GP :3," which is unclear.

N-Acetyl-Cysteine (NAC) was found to improve hair parameters in men with early-onset androgenetic alopecia, showing increased terminal hair count and decreased vellus hair count, with good tolerability. NAC, used alone or with minoxidil, may help due to its antioxidant properties, though its effectiveness can vary among individuals.

The conversation discusses alternative and unorthodox hair loss treatments, including RU58841, nandrolone, and dianabol, as well as theoretical approaches involving high doses of estrogen and selective estrogen receptor modulators. These methods are considered extreme and potentially harmful but are explored for those unable to tolerate traditional 5-alpha reductase inhibitors.

People are hopeful about future hair loss treatments like PP405, GT20029, and VDPHL01, while some are currently using finasteride and minoxidil. There is skepticism about the effectiveness of new treatments, and some advise against hair transplants until more promising drugs are available.

Discussing results, side effects and potential sources of pyrilutamide for hair loss treatment alongside RU58841 and other treatments such as Minoxidil and finasteride.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

A user improved their hair loss from NW3+ to NW1.5 over three years using a regimen of dutasteride, finasteride, Nizoral, biotin, and collagen. They experienced some side effects and adjusted dosages over time, and noted additional benefits like better skin and muscle gain.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.

The conversation discusses hair regrowth possibilities using finasteride, minoxidil, microneedling, and dutasteride, with the user experiencing improvement from NW4 to NW2. Achieving NW0 is deemed unrealistic, but further regrowth may be possible with patience and potentially a hair transplant.